JP2010526101A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526101A5
JP2010526101A5 JP2010506688A JP2010506688A JP2010526101A5 JP 2010526101 A5 JP2010526101 A5 JP 2010526101A5 JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010526101 A5 JP2010526101 A5 JP 2010526101A5
Authority
JP
Japan
Prior art keywords
use according
compound
composition
unit dose
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010506688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526101A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/062518 external-priority patent/WO2008137753A2/en
Publication of JP2010526101A publication Critical patent/JP2010526101A/ja
Publication of JP2010526101A5 publication Critical patent/JP2010526101A5/ja
Withdrawn legal-status Critical Current

Links

JP2010506688A 2007-05-02 2008-05-02 直接作用型および可逆的p2y12阻害剤の静脈および経口投与 Withdrawn JP2010526101A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (2)

Publication Number Publication Date
JP2010526101A JP2010526101A (ja) 2010-07-29
JP2010526101A5 true JP2010526101A5 (pt-PT) 2011-06-23

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506688A Withdrawn JP2010526101A (ja) 2007-05-02 2008-05-02 直接作用型および可逆的p2y12阻害剤の静脈および経口投与

Country Status (17)

Country Link
US (2) US20090048216A1 (pt-PT)
EP (1) EP2079464A2 (pt-PT)
JP (1) JP2010526101A (pt-PT)
KR (1) KR20100029746A (pt-PT)
CN (1) CN101795682A (pt-PT)
AU (1) AU2008247483A1 (pt-PT)
BR (1) BRPI0811476A2 (pt-PT)
CA (1) CA2686203A1 (pt-PT)
CO (1) CO6241104A2 (pt-PT)
EA (1) EA200901473A1 (pt-PT)
EC (1) ECSP099778A (pt-PT)
GT (1) GT200900284A (pt-PT)
IL (1) IL201834A0 (pt-PT)
MA (1) MA31663B1 (pt-PT)
MX (1) MX2009011843A (pt-PT)
TN (1) TN2009000451A1 (pt-PT)
WO (1) WO2008137753A2 (pt-PT)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔4-(6-할로-7-치환된-2,4-디옥소-1,4-디히드로-2h-퀴나졸린-3-일)-페닐〕-5-클로로티오펜-2-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
KR20090115953A (ko) * 2007-03-06 2009-11-10 노파르티스 아게 염증성 또는 알레르기성 상태의 치료에 적합한 바이시클릭 유기 화합물
WO2008137809A2 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
KR20110115578A (ko) * 2008-12-30 2011-10-21 트롬보로직 에이피에스 장기 부전이 발달할 증가된 위험이 있는 중증 질환 환자의 확인 방법 및 이의 치료를 위한 화합물
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
WO2011076749A2 (en) * 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2646827A1 (en) * 2010-12-01 2013-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ, インコーポレイテッド 式(i)の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
MX2019009559A (es) 2017-03-15 2019-10-15 Idorsia Pharmaceuticals Ltd Administracion subcutanea de un antagonista del receptor p2y12.
EP3641784A1 (en) 2017-06-23 2020-04-29 Chiesi Farmaceutici S.p.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
KR101423483B1 (ko) 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔4-(6-할로-7-치환된-2,4-디옥소-1,4-디히드로-2h-퀴나졸린-3-일)-페닐〕-5-클로로티오펜-2-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법

Similar Documents

Publication Publication Date Title
JP2010526101A5 (pt-PT)
JP2020033360A5 (pt-PT)
US11896567B2 (en) Combination composition
JP2011173928A5 (pt-PT)
JP2009102342A5 (pt-PT)
JP2014515373A5 (pt-PT)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
ES2865278T3 (es) Amantadina para mejorar la marcha en esclerosis múltiple
JP2020510043A5 (pt-PT)
ES2508490T3 (es) Formulación de trimetazidina con diferentes perfiles de liberación
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
ES2671926T3 (es) Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico
AU2011274652B2 (en) A combination composition comprising ibuprofen and paracetamol
AU2010277725B2 (en) Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients
CN114588164B (zh) 瑞马唑仑在预防围术期低体温和寒战中的应用
CA2964684A1 (en) Composition for the treatment of conditions involving muscular pain
JP2024502598A (ja) ケタミンの経口投与
JP2013500964A (ja) 静脈内イブプロフェンを用いた重篤な病気の患者の治療
ES2782898T3 (es) Métodos de administración de compuestos agonistas de la trombopoyetina
ES2952013T3 (es) Combinación de ibuprofeno y tramadol para aliviar el dolor
JP2008527034A5 (pt-PT)
CN102247330B (zh) 一种以红花黄色素为原料制备的缓释片剂及其制备方法
BRPI0617184A2 (pt) formulação de pralnacasan com liberação retardada
Myers et al. Infection and pheochromocytoma
CN103933034B (zh) 一种含有木犀草素的药物组合物及应用